Literature DB >> 1639933

Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer.

L A Burmeister1, M O Goumaz, C N Mariash, J H Oppenheimer.   

Abstract

We have compared the dose of levothyroxine (L-T4) required to suppress serum TSH to given levels in two clinical groups: 1) 44 patients with thyroid cancer whose thyroid glands had been ablated by surgical thyroidectomy and 131I treatment, and 2) 113 patients with thyroidal failure due either to spontaneous primary hypothyroidism (31 patients) or after 131I treatment for Graves' hyperthyroidism (82 patients). The dose of L-T4 needed to attain serum TSH levels in the euthyroid range (0.5-6.2 microU/mL) was significantly greater (P less than 0.01) in patients with thyroid cancer (2.11 micrograms/kg.day) than in the patients with primary hypothyroidism associated with nonmalignant disease (1.63 micrograms/kg.day). Similarly, patients with thyroid cancer required a higher dose of L-T4 to suppress serum TSH to a given subnormal level. These findings suggest that the secretion of hormone from residual thyroid tissue in patients who have not been subjected to near-total thyroid ablation contributes substantially to the circulating levels of serum T4 and T3. We, therefore, infer that residual thyroidal secretion in the patients with hypothyroidism due to benign causes is relatively independent of TSH stimulation. Further subdivision of patients with benign hypothyroidism revealed that patients with Graves' who developed hypothyroidism after 131I treatment showed a lower mean dose requirement than patients with spontaneous hypothyroidism. This raises the possibility that continued secretion of thyroid-stimulating immunoglobulin in such patients might account for the lower dose requirement in the combined group with hypothyroidism. Our studies also have allowed us to make serial observations in 4 patients with thyroid cancer who exhibited elevated levels of serum thyroglobulin. In this limited series, maximal suppression of serum thyroglobulin was produced by doses of L-T4, which reduced circulating TSH to 0.4 mU/L.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1639933     DOI: 10.1210/jcem.75.2.1639933

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

Review 1.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

2.  Levothyroxine replacement doses are affected by gender and weight, but not age.

Authors:  Madhuri Devdhar; Rebecca Drooger; Marieta Pehlivanova; Gurdeep Singh; Jacqueline Jonklaas
Journal:  Thyroid       Date:  2011-07-13       Impact factor: 6.568

Review 3.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

4.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

5.  New questions regarding bioequivalence of levothyroxine preparations: a clinician's response.

Authors:  William L Green
Journal:  AAPS J       Date:  2005-03-30       Impact factor: 4.009

Review 6.  Initial treatment of differentiated thyroid carcinoma.

Authors:  B R Haugen
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

7.  Thyroid carcinoma in childhood: management and follow up of 11 cases.

Authors:  A Jocham; I Joppich; W Hecker; D Knorr; H P Schwarz
Journal:  Eur J Pediatr       Date:  1994-01       Impact factor: 3.183

Review 8.  Hürthle cell carcinoma.

Authors:  E Yutan; O H Clark
Journal:  Curr Treat Options Oncol       Date:  2001-08

9.  Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation.

Authors:  Silvia Morelli; Gianpaolo Reboldi; Sonia Moretti; Elisa Menicali; Nicola Avenia; Efisio Puxeddu
Journal:  Endocrine       Date:  2015-11-04       Impact factor: 3.633

Review 10.  Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and management.

Authors:  Yvette Carter; Rebecca S Sippel; Herbert Chen
Journal:  Oncologist       Date:  2013-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.